Rx.V
RX.V operates in the pharmaceuticals industry, generating revenue primarily through the development and commercialization of prescription medications and related healthcare products.
Business. RX.V operates in the pharmaceuticals industry, generating revenue primarily through the development and commercialization of prescription medications and related healthcare products.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
RX.V operates in the pharmaceuticals industry, generating revenue primarily through the development and commercialization of prescription medications and related healthcare products.
RX.V maintains a strong liquidity position, with a current ratio of 5.51, indicating the company can easily cover its short-term liabilities with its current assets. The company's liquidity_fpt score suggests a medium liquidity risk, which is consistent with its strong cash flow generation. Free cash flow of 7.56 million CAD supports operational flexibility and potential reinvestment.
Profitability metrics for RX.V are robust, with a return on equity of 21.73% and a return on assets of 18.23%. These figures exceed the typical thresholds for the pharmaceutical industry, suggesting efficient use of equity and assets to generate returns. The company's operating margin, derived from its operating income of 11.19 million CAD on revenue of 43.05 million CAD, is also strong, indicating effective cost management.
Geographically and segment-wise, RX.V's revenue concentration is not disclosed in the available data. However, the company's primary business activity is in pharmaceuticals, and its exposure is likely concentrated in its core markets. The lack of detailed segment data limits the ability to assess geographic or product diversification.
RX.V's growth trajectory is supported by its strong cash flow and profitability. The company's outlook for the current fiscal year indicates a positive direction, with no specific numeric deltas provided. The absence of capital expenditure in the latest financials suggests a focus on maintaining operations rather than expansion.
Risk factors for RX.V include a medium liquidity risk, primarily due to a negative net cash position after accounting for total debt. The company's dilution risk is low, with no significant dilution potential identified in the basic shares outstanding. However, the presence of long-term debt, albeit minimal at 841,100 CAD, introduces a minor credit risk.
Recent events and filings for RX.V do not include any major announcements or regulatory actions. The company's financials remain stable, with no significant changes in its capital structure or operational performance. Analysts have provided a mean price target of 16.50 CAD, with a single "buy" recommendation and no "strong buy" or "hold" ratings.
- RX.V demonstrates strong liquidity with a current ratio of 5.51, indicating a solid ability to meet short-term obligations.
- The company's profitability is robust, with a return on equity of 21.73% and a return on assets of 18.23%.
- RX.V's capital structure is relatively conservative, with a low debt-to-equity ratio of 0.02.
- Analysts have provided a mean price target of 16.50 CAD, with a single "buy" recommendation.
- The company's growth trajectory is supported by strong cash flow and profitability, though no specific growth metrics are provided.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,94 |
| Revenue | —no estimate | —no estimate | 68,6M CAD |
| Operating income | —no estimate | —no estimate | —no estimate |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- RX.V Market data — financials · 2026-05-29
- BioSyent Inc Market data — analyst estimates · 2026-05-29